Cargando…

DUSP1 Signaling Pathway Regulates Cytarabine Sensitivity in Acute Myeloid Leukemia

Objectives: Dual specificity phosphatase 1 (DUSP1) is high-expressed in various cancers and plays an important role in the cellular response to agents that damage DNA. We aimed to investigate the expressions and mechanisms of DUSP1 signaling pathway regulating cytarabine (Ara-C) resistance in acute...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Huali, Ren, Yanling, Zhou, Xinping, Chen, Qi, Liu, Yanmei, Zhu, Chumeng, Ruan, Yanyun, Ruan, Hongli, Tong, Hongyan, Ying, Shenpeng, Lin, Peipei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10594969/ https://www.ncbi.nlm.nih.gov/pubmed/37872685 http://dx.doi.org/10.1177/15330338231207765

Ejemplares similares

TROP2 modulates the progression in papillary thyroid carcinoma
por: Sun, Huali, et al.
Publicado: (2021)

Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota
por: Liu, Junmin, et al.
Publicado: (2022)

Successful treatment of Candida tropicalis osteomyelitis with Micafungin in a leukemia patient
por: Ma, Liya, et al.
Publicado: (2016)

MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy
por: Zhang, Hao, et al.
Publicado: (2020)

Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
por: Visser, Nienke, et al.
Publicado: (2021)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia
por: Momparler, Richard L
Publicado: (2013)

Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia
por: Zhou, Shiyong, et al.
Publicado: (2017)

Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance
por: Åbacka, Hannah, et al.
Publicado: (2021)

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia
por: Anderson, Rebecca, et al.
Publicado: (2022)

Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia
por: Leonard, Sarah M., et al.
Publicado: (2014)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

TFE3 Regulates the Function of the Autophagy-Lysosome Pathway to Drive the Invasion and Metastasis of Papillary Thyroid Carcinoma
por: Lu, Hongsheng, et al.
Publicado: (2021)

Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience
por: Bashir, Yasir, et al.
Publicado: (2015)

Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells
por: Li, Peng, et al.
Publicado: (2016)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Safety and Feasibility of Outpatient High Dose Cytarabine for Acute Myeloid Leukemia in the Brazilian Amazon
por: Rodrigues, Amanda Lopes Maia, et al.
Publicado: (2020)

Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
por: Serhan, Nizar, et al.
Publicado: (2020)

Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death
por: Heo, Sook-Kyoung, et al.
Publicado: (2020)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

Combination of cyclophosphamide and cytarabine as induction regimen for newly diagnosed adult acute myeloid leukemia
por: Liu, Qingguo, et al.
Publicado: (2020)

Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
por: Konopleva, Marina Y., et al.
Publicado: (2022)

A clinical report on high‑dose cytarabine therapy for children with acute myeloid leukemia
por: Wu, Ziliang, et al.
Publicado: (2022)

Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2023)

T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis
por: Zhu, Chumeng, et al.
Publicado: (2021)

Heteronemin, a marine natural product, sensitizes acute myeloid leukemia cells towards cytarabine chemotherapy by regulating farnesylation of Ras
por: Saikia, Minakshi, et al.
Publicado: (2018)

The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes
por: Lin, Peipei, et al.
Publicado: (2019)

Synergistic suppression effect on tumor growth of acute myeloid leukemia by combining cytarabine with an engineered oncolytic vaccinia virus
por: Peng, Jiamin, et al.
Publicado: (2018)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis
por: Li, Wei, et al.
Publicado: (2014)

Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells
por: Bista, Ranjan, et al.
Publicado: (2017)

Observation of clinical efficacy and toxic and side effects of pirarubicin combined with cytarabine on acute myeloid leukemia
por: Lv, Suqin, et al.
Publicado: (2019)

Increased Expression of Micro-RNA-23a Mediates Chemoresistance to Cytarabine in Acute Myeloid Leukemia
por: Hatzl, Stefan, et al.
Publicado: (2020)

Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia
por: Barwe, Sonali P., et al.
Publicado: (2022)

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
por: Arwanih, Elly Y, et al.
Publicado: (2022)

Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy
por: Rodríguez-Macías, Gabriela, et al.
Publicado: (2023)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
por: Lee, Julia S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0pp645qst828bgt8hiuhqhcop0